Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Glob Heart ; 17(1): 57, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36051320

RESUMO

Background: There is a lack of epidemiological data around heart failure (HF) in Latin America; the potential impact description of this disease in middle-income countries is relevant. Objective: This study aimed to describe the characteristics and healthcare resource utilization patterns of HF patients at baseline and six-month follow-up. Methods: This retrospective observational study used data from the RECOLFACA (Registro Colombiano de Falla Cardíaca) registry, which includes data obtained from the examination of clinical records from 2,528 patients in 60 Colombian healthcare institutions. Baseline and six-month follow-up data were evaluated from patients with previous hospital admissions due to HF during the 12 months prior to enrollment. Results: This study analyzed 2,045 patients (42.8% female) with a mean age of 67.71 ± 13.64 years. The most common etiologies were ischemic (44.4%) and hypertensive heart disease (38.5%). At baseline, 53.4% of patients were classified with NYHA class II, and 73.6% had a reduced left ventricle ejection fraction (LVEF). A year prior to entering the registry, patients were hospitalized an average of 1.4 ± 1.1 times due to HF. Prescription of evidence-based treatment at baseline included sacubitril/valsartan (10%), ACEI (33%), ARB (41%), beta-blocker (79%), diuretics (68%), and MRA (56%). The average quality of life score measured using the EQ-5D-3L questionnaire was 78.7 ± 20.8 at baseline and 82.3 ± 20.1 at the six-month follow-up. The mortality rate was 6.7%. Conclusions: The use of information from the RECOLFACA registry allowed characterization as well as analyses of healthcare resource utilization of patients with heart failure in Colombia. The results of this study show that multiple evidence-based treatments for HF are being widely used in Colombia, but there seems to be room for improvement regarding some interventions for the treatment of patients with HF.


Assuntos
Antagonistas de Receptores de Angiotensina , Insuficiência Cardíaca , Idoso , Idoso de 80 Anos ou mais , Aminobutiratos , Antagonistas de Receptores de Angiotensina/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Compostos de Bifenilo , Feminino , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/epidemiologia , Insuficiência Cardíaca/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Sistema de Registros , Volume Sistólico , Resultado do Tratamento
2.
CES med ; 18(2): 9-18, jul.-dic. 2004. graf
Artigo em Espanhol | LILACS | ID: lil-459078

RESUMO

El estudio de Framingham desempeñó un papel vital para la definición de los factores de riesgo que contribuyen a la aparición de EC. Su aporte fundamental al conocimiento fue la posibilidad de hacer el pronóstico sobre la probabilidad de presentarse una EC, generándose la escala de Framingham. Objetivo: Responder a la pregunta: ¿Cuál es el comportamiento de la Escala de Framingham en una población urbana de la ciudad de Medellín? ¿Cómo se distribuye nuestra población según nivel de riesgo? Métodos: Se aplicó la metodología de estudios descriptivos de corte. El cálculo de la muestra aplicó la fórmula de Wayne W.Daniel, dando un tamaño mínimo de muestra de 309 personas. La información se recolectó por personal de salud debidamente entrenado y los datos se llevaron una base de datos electrónica que luego se exportó al programa SPSS. Los ejes de análisis utilizados fueron la edad y el sexo. A partir de lo anterior se estimó la prevalencia para los factores de riesgo evaluados dentro de la escala. Finalmente se calculó la distribución de riesgo de la población estudiada para el total y para uno de los sexos...


Assuntos
Doenças Cardiovasculares , Doença das Coronárias , Fatores de Risco , Doenças Cardiovasculares/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...